04:51
BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.
Jin10 Data August 19 - BeiGene announced on August 19 on the interactive platform that MCLA-129 is a bispecific antibody targeting EGFR and c-Met dual targets, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. If there are significant research developments, the company will disclose them in a timely manner.
- 6